Cue Biopharma (STU:1UC) Institutional Ownership : 15.96% (As of May. 28, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cue Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cue Biopharma's institutional ownership is 15.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cue Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cue Biopharma's Float Percentage Of Total Shares Outstanding is 99.29%.

Cue Biopharma Institutional Ownership Historical Data

The historical data trend for Cue Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Institutional Ownership Chart

Cue Biopharma Historical Data

The historical data trend for Cue Biopharma can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	19.14	18.57	18.83	16.47	16.54	16.28	16.74	16.73	16.14	15.96

Cue Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Cue Biopharma (STU:1UC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (STU:1UC) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CUE:USA

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Cue Biopharma (STU:1UC) Headlines

No Headlines